Published in Int J Clin Pract on November 28, 2013
2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma. Gut Liver (2015) 1.23
2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. Korean J Radiol (2015) 1.14
Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma. Oncologist (2016) 0.99
Management of hepatocellular carcinoma with portal vein thrombosis. World J Gastroenterol (2015) 0.98
Recent advances in multidisciplinary management of hepatocellular carcinoma. World J Hepatol (2015) 0.98
Hepatocellular carcinoma: Surgeon's view on latest findings and future perspectives. World J Hepatol (2015) 0.91
Hepatobiliary Tumors: Update on Diagnosis and Management. J Clin Transl Hepatol (2015) 0.89
Hepatocellular carcinoma: From diagnosis to treatment. World J Hepatol (2015) 0.89
Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. Invest New Drugs (2015) 0.87
Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis. Oncol Lett (2015) 0.85
Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age. World J Gastroenterol (2014) 0.84
Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma. Cancer Sci (2014) 0.84
Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: The jury is still out. World J Hepatol (2014) 0.83
Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib. Therap Adv Gastroenterol (2016) 0.82
Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review. World J Gastroenterol (2016) 0.81
Comparative dosing and efficacy of sorafenib in hepatocellular cancer patients with varying liver dysfunction. J Gastrointest Oncol (2015) 0.81
Poly(lactide-co-glycolide) microspheres for MRI-monitored delivery of sorafenib in a rabbit VX2 model. Biomaterials (2015) 0.81
Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON. J Gastroenterol (2016) 0.80
Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma. Oncotarget (2016) 0.79
Diagnostics and Treatment of Hepatocellular Carcinoma in 2016: Standards and Developments. Visc Med (2016) 0.79
Feasibility and safety of sorafenib treatment in hepatocellular carcinoma patients with spontaneous rupture. World J Gastroenterol (2014) 0.78
Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment. Liver Cancer (2016) 0.78
Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study. Int J Clin Oncol (2015) 0.78
Response to chemotherapy improves hepatic reserve for patients with hepatocellular carcinoma and Child-Pugh B cirrhosis. Cancer Sci (2016) 0.77
Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int (2017) 0.77
Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study. Oncotarget (2016) 0.76
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial. J Gastroenterol (2016) 0.76
Locoregional Therapy for Hepatocellular Carcinoma with and without Extrahepatic Spread. J Vasc Interv Radiol (2015) 0.75
Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort. World J Gastroenterol (2017) 0.75
Systemic treatment for hepatocellular carcinoma: Still unmet expectations. World J Hepatol (2017) 0.75
PharmGKB summary: sorafenib pathways. Pharmacogenet Genomics (2017) 0.75
Potentiation of the anticancer effects of everolimus using a dual mTORC1/2 inhibitor in hepatocellular carcinoma cells. Oncotarget (2016) 0.75
Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives. J Hepatocell Carcinoma (2014) 0.75
Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data. Cancer Res Treat (2016) 0.75
Ultrasound Elastography Used for Preventive Non-Invasive Screening in Early Detection of Liver Fibrosis. J Clin Med Res (2016) 0.75
Evolving role of Sorafenib in the management of hepatocellular carcinoma. World J Clin Oncol (2017) 0.75
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma. Target Oncol (2017) 0.75
Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to loco-regional therapies. Cancer Sci (2017) 0.75
Partial liver resection results in a significantly better long-term survival than locally ablative procedures even in elderly patients. J Cancer Res Clin Oncol (2016) 0.75
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Management of hepatocellular carcinoma: an update. Hepatology (2011) 33.57
Management of hepatocellular carcinoma. Hepatology (2005) 27.42
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol (2008) 23.93
Hepatocellular carcinoma. Lancet (2003) 22.54
Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology (2012) 10.00
Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology (2011) 4.60
The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol (2006) 4.17
Hepatocellular carcinoma: the need for progress. J Clin Oncol (2005) 3.11
Chemoembolization for hepatocellular carcinoma. Gastroenterology (2004) 2.89
Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int (2008) 2.10
Staging systems in hepatocellular carcinoma. HPB (Oxford) (2005) 1.71
How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer (2000) 1.68
First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study. Int J Clin Pract (2012) 1.65
Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study. Int J Clin Pract (2010) 1.31
Risk factors of hepatocellular carcinoma--current status and perspectives. Asian Pac J Cancer Prev (2012) 1.30
Hepatocellular carcinoma development in cirrhosis. Best Pract Res Clin Gastroenterol (2007) 1.18
Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol (2010) 1.06
[Epidemiology, natural history and pathogenesis of hepatocellular carcinoma]. Cancer Radiother (2011) 0.99
Effect of a new immunosuppressive agent, FK 506, on heterotopic cardiac allotransplantation in the rat. Transplant Proc (1987) 12.04
Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature (1986) 9.63
Recent human influenza A (H1N1) viruses are closely related genetically to strains isolated in 1950. Nature (1978) 5.43
The SHORT-ROOT gene controls radial patterning of the Arabidopsis root through radial signaling. Cell (2000) 5.38
Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res Mol Brain Res (1998) 4.87
Comparison of complete amino acid sequences and receptor-binding properties among 13 serotypes of hemagglutinins of influenza A viruses. Virology (1991) 4.85
Efficient in utero gene transfer system to the developing mouse brain using electroporation: visualization of neuronal migration in the developing cortex. Neuroscience (2001) 4.45
The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med (1988) 4.31
Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver--update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultraschall Med (2012) 4.21
Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery (1990) 3.93
Infection with HIV is associated with elevated IL-6 levels and production. J Immunol (1990) 3.89
Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Immunity (1996) 3.66
Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). Proc Natl Acad Sci U S A (1985) 3.46
Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol Pharmacol (2002) 3.36
Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology (1997) 3.28
Scrambler and yotari disrupt the disabled gene and produce a reeler-like phenotype in mice. Nature (1997) 3.22
Surgery for small liver cancers. Semin Surg Oncol (1993) 3.00
Primary structure, synthesis, and biological activity of rat endothelin, an endothelium-derived vasoconstrictor peptide. Proc Natl Acad Sci U S A (1988) 2.99
Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg (2000) 2.92
Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Aliment Pharmacol Ther (2014) 2.88
Common inhibitory mechanism in human inferior prefrontal cortex revealed by event-related functional MRI. Brain (1999) 2.84
Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology (1992) 2.83
Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer (2010) 2.82
The reeler gene-associated antigen on Cajal-Retzius neurons is a crucial molecule for laminar organization of cortical neurons. Neuron (1995) 2.82
Hepatic lidocaine metabolism and liver histology in patients with chronic hepatitis and cirrhosis. Hepatology (1994) 2.81
Extracellular signal-dependent nuclear import of Stat1 is mediated by nuclear pore-targeting complex formation with NPI-1, but not Rch1. EMBO J (1997) 2.80
Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production. Proc Natl Acad Sci U S A (1987) 2.76
Experimental investigation of geologically produced antineutrinos with KamLAND. Nature (2005) 2.75
Change in receptor-binding specificity of recent human influenza A viruses (H3N2): a single amino acid change in hemagglutinin altered its recognition of sialyloligosaccharides. Virology (2000) 2.70
Mouse-Musashi-1, a neural RNA-binding protein highly enriched in the mammalian CNS stem cell. Dev Biol (1996) 2.68
Mapping the extended substrate binding site of cathepsin G and human leukocyte elastase. Studies with peptide substrates related to the alpha 1-protease inhibitor reactive site. J Biol Chem (1979) 2.66
Dynamic changes of the inflammation-based index predict mortality following chemoembolisation for hepatocellular carcinoma: a prospective study. Aliment Pharmacol Ther (2014) 2.66
A role for Cajal-Retzius cells and reelin in the development of hippocampal connections. Nature (1997) 2.61
Light-induced superconductivity in a stripe-ordered cuprate. Science (2011) 2.54
Molecular cloning and expression of a member of the aquaporin family with permeability to glycerol and urea in addition to water expressed at the basolateral membrane of kidney collecting duct cells. Proc Natl Acad Sci U S A (1994) 2.54
No-mortality liver resection for hepatocellular carcinoma in cirrhotic and noncirrhotic patients: is there a way? A prospective analysis of our approach. Arch Surg (1999) 2.47
High prevalence of anti-hepatitis B virus serological markers in patients with hepatitis C virus related chronic liver disease in Japan. Gut (1999) 2.46
Perioperative blood transfusion promotes recurrence of hepatocellular carcinoma after hepatectomy. Surgery (1994) 2.45
The three subfamilies of leucine-rich repeat-containing G protein-coupled receptors (LGR): identification of LGR6 and LGR7 and the signaling mechanism for LGR7. Mol Endocrinol (2000) 2.37
STAT3 is required for the gp130-mediated full activation of the c-myc gene. J Exp Med (1999) 2.36
Right lobe living donor liver transplantation. Transplantation (1999) 2.31
Recurrence of hepatocellular carcinoma after surgery. Br J Surg (1996) 2.27
Are left-sided gallbladders really located on the left side? Ann Surg (1997) 2.24
Identification and initial characterization of four novel members of the interleukin-1 family. J Biol Chem (2000) 2.24
Reelin is a secreted glycoprotein recognized by the CR-50 monoclonal antibody. J Neurosci (1997) 2.17
Sensitive substrates for human leukocyte and porcine pancreatic elastase: a study of the merits of various chromophoric and fluorogenic leaving groups in assays for serine proteases. Anal Biochem (1979) 2.15
Studies of the induction and maintenance of long-term graft acceptance by treatment with FK506 in heterotopic cardiac allotransplantation in rats. Transplantation (1987) 2.15
A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology (1999) 2.11
Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett (2001) 2.11
No-go dominant brain activity in human inferior prefrontal cortex revealed by functional magnetic resonance imaging. Eur J Neurosci (1998) 2.10
Signaling mechanisms through gp130: a model of the cytokine system. Cytokine Growth Factor Rev (1997) 2.08
Differentiation and growth arrest signals are generated through the cytoplasmic region of gp130 that is essential for Stat3 activation. EMBO J (1996) 2.07
"Leaner and less fit" children have a better cardiometabolic profile than their "heavier and more fit" peers: the Healthy Growth Study. Nutr Metab Cardiovasc Dis (2013) 2.04
Prophylactic pancreatic stent placement and post-ERCP pancreatitis: a systematic review and meta-analysis. Endoscopy (2010) 1.99
Splenectomy in patients with hepatocellular carcinoma and hypersplenism. J Am Coll Surg (2000) 1.99
Disabled-1 acts downstream of Reelin in a signaling pathway that controls laminar organization in the mammalian brain. Development (1998) 1.98
Cellular mechanism of action by a novel vasoconstrictor endothelin in cultured rat vascular smooth muscle cells. Biochem Biophys Res Commun (1988) 1.98
Temperature-sensitive simian virus 40 mutant defective in a late function. J Virol (1970) 1.95
Development of a polymerase chain reaction-based diagnosis of Trichomonas vaginalis. J Clin Microbiol (1992) 1.91
Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation (1999) 1.89
Transient activation of inferior prefrontal cortex during cognitive set shifting. Nat Neurosci (1998) 1.89
Dynamic imaging of pancreatic diseases by contrast enhanced coded phase inversion harmonic ultrasonography. Gut (2004) 1.89
Acute hydrothorax in continuous ambulatory peritoneal dialysis--a collaborative study of 161 centers. Am J Nephrol (1989) 1.88
Primary intestinal lymphangiectasia successfully treated with octreotide. J Gastroenterol (2001) 1.87
Biochemical evidence that "new" influenza virus strains in nature may arise by recombination (reassortment). Proc Natl Acad Sci U S A (1978) 1.86
Autoregulation of the Stat3 gene through cooperation with a cAMP-responsive element-binding protein. J Biol Chem (1998) 1.83
Pathologic support for limited hepatectomy in the treatment of liver metastases from colorectal cancer. Ann Surg (1995) 1.81
Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med (2001) 1.80
MicroRNA-146a and human disease. Scand J Immunol (2010) 1.80
Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim Biophys Acta (2002) 1.79
Predictive factors for postoperative recurrence of hepatocellular carcinoma. Gastroenterology (1994) 1.76
Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J (2000) 1.75
The right gastroepiploic artery graft. Clinical and angiographic midterm results in 200 patients. J Thorac Cardiovasc Surg (1993) 1.73
Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy. Hepatology (1999) 1.73
Detection of influenza viruses in throat swab by using polymerase chain reaction. Microbiol Immunol (1991) 1.72
Predictive value of gross classification of hepatocellular carcinoma on recurrence and survival after hepatectomy. J Hepatol (2000) 1.71
Genetic relatedness between A/Swine/Iowa/15/30(H1N1) and human influenza viruses. Virology (1984) 1.70
A single nucleotide polymorphism in the E-cadherin gene promoter alters transcriptional activities. Cancer Res (2000) 1.70
Complications of transjugular intrahepatic portosystemic shunt: a comprehensive review. Radiographics (1993) 1.68
Possible role of Helicobacter pylori infection in early gastric cancer development. Cancer (1994) 1.68
Outbreaks of Norwalk-like virus-associated gastroenteritis traced to shellfish: coexistence of two genotypes in one specimen. Epidemiol Infect (1996) 1.68
K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. Carcinogenesis (1999) 1.67
Hepatocyte transplantation as a bridge to orthotopic liver transplantation in terminal liver failure. Transplantation (1997) 1.67
Gab1 acts as an adapter molecule linking the cytokine receptor gp130 to ERK mitogen-activated protein kinase. Mol Cell Biol (1998) 1.66
First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study. Int J Clin Pract (2012) 1.65
Studies of the effects of FK506 on renal allografting in the beagle dog. Transplantation (1987) 1.65
Phenotype and genotype in mucolipidoses II and III alpha/beta: a study of 61 probands. J Med Genet (2009) 1.64